Chinmay Tushar Jani, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Takotsubo Cardiomyopathy | 1 | 2021 | 125 | 0.680 |
Why?
|
| Carcinoma, Lobular | 1 | 2023 | 484 | 0.650 |
Why?
|
| Carcinoma in Situ | 1 | 2023 | 806 | 0.590 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 975 | 0.540 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2023 | 949 | 0.520 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 773 | 0.470 |
Why?
|
| Leukemia | 1 | 2022 | 1511 | 0.470 |
Why?
|
| Disabled Persons | 1 | 2023 | 1212 | 0.460 |
Why?
|
| European Union | 3 | 2022 | 158 | 0.450 |
Why?
|
| Incidence | 11 | 2023 | 20947 | 0.440 |
Why?
|
| Osteoporosis | 1 | 2021 | 1580 | 0.400 |
Why?
|
| Guillain-Barre Syndrome | 2 | 2023 | 120 | 0.390 |
Why?
|
| Asia | 2 | 2022 | 610 | 0.370 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 4262 | 0.340 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2208 | 0.310 |
Why?
|
| Neoplasms | 7 | 2023 | 21683 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 20822 | 0.290 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 13102 | 0.280 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2023 | 1683 | 0.240 |
Why?
|
| Subacute Combined Degeneration | 1 | 2023 | 4 | 0.230 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2023 | 117 | 0.230 |
Why?
|
| Priapism | 1 | 2022 | 31 | 0.220 |
Why?
|
| Austria | 1 | 2022 | 203 | 0.210 |
Why?
|
| Myelitis | 1 | 2022 | 53 | 0.200 |
Why?
|
| Mediastinal Diseases | 1 | 2022 | 89 | 0.200 |
Why?
|
| Phenytoin | 1 | 2022 | 197 | 0.200 |
Why?
|
| Bronchial Neoplasms | 1 | 2021 | 112 | 0.200 |
Why?
|
| Smooth Muscle Tumor | 1 | 2021 | 67 | 0.200 |
Why?
|
| Hypernatremia | 1 | 2021 | 82 | 0.190 |
Why?
|
| Humans | 43 | 2023 | 744343 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 1671 | 0.190 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2020 | 65 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13695 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 11124 | 0.180 |
Why?
|
| Hyperplasia | 1 | 2023 | 1185 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2022 | 281 | 0.170 |
Why?
|
| Europe | 2 | 2023 | 3339 | 0.170 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2022 | 266 | 0.160 |
Why?
|
| Catheter Ablation | 2 | 2023 | 2758 | 0.160 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2023 | 545 | 0.150 |
Why?
|
| Male | 19 | 2023 | 350118 | 0.140 |
Why?
|
| World Health Organization | 1 | 2022 | 1318 | 0.140 |
Why?
|
| Necrosis | 1 | 2021 | 1643 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2023 | 810 | 0.140 |
Why?
|
| Drug Approval | 1 | 2023 | 742 | 0.140 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 315 | 0.140 |
Why?
|
| Propofol | 1 | 2022 | 629 | 0.140 |
Why?
|
| Diphosphonates | 1 | 2021 | 623 | 0.140 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2020 | 579 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 2274 | 0.140 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 740 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2022 | 986 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.130 |
Why?
|
| Cocaine | 1 | 2021 | 1007 | 0.130 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 912 | 0.130 |
Why?
|
| Chest Pain | 1 | 2022 | 1114 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1177 | 0.120 |
Why?
|
| Female | 18 | 2023 | 380194 | 0.120 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 1377 | 0.120 |
Why?
|
| Immunity | 1 | 2020 | 1012 | 0.120 |
Why?
|
| Biopsy | 2 | 2023 | 6756 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 808 | 0.110 |
Why?
|
| Vaccines | 1 | 2022 | 822 | 0.110 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 5034 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 2494 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 1164 | 0.110 |
Why?
|
| United States | 7 | 2023 | 69872 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1889 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2021 | 6459 | 0.100 |
Why?
|
| Mortality | 1 | 2022 | 2864 | 0.100 |
Why?
|
| Stroke | 2 | 2023 | 9981 | 0.090 |
Why?
|
| Seizures | 1 | 2022 | 2859 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 3086 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2282 | 0.080 |
Why?
|
| Cough | 2 | 2022 | 555 | 0.080 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 1965 | 0.080 |
Why?
|
| Thrombosis | 1 | 2022 | 2968 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2020 | 5007 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3143 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4034 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2021 | 7729 | 0.070 |
Why?
|
| Lung | 2 | 2022 | 9856 | 0.070 |
Why?
|
| Electronic Health Records | 3 | 2023 | 4468 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5510 | 0.060 |
Why?
|
| Dyspnea | 2 | 2022 | 1303 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5221 | 0.060 |
Why?
|
| Hungary | 1 | 2023 | 84 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 5686 | 0.060 |
Why?
|
| Adult | 8 | 2023 | 214055 | 0.060 |
Why?
|
| Wisconsin | 1 | 2023 | 124 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10180 | 0.050 |
Why?
|
| Nitrous Oxide | 1 | 2023 | 177 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11524 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 12959 | 0.050 |
Why?
|
| Lip | 1 | 2023 | 195 | 0.050 |
Why?
|
| Polyuria | 1 | 2021 | 39 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 6487 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 339 | 0.050 |
Why?
|
| Inflammation | 1 | 2020 | 10638 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 390 | 0.050 |
Why?
|
| Middle Aged | 6 | 2023 | 213383 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2021 | 341 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2022 | 676 | 0.040 |
Why?
|
| Anticoagulants | 2 | 2023 | 4599 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 602 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2021 | 604 | 0.040 |
Why?
|
| Morbidity | 1 | 2023 | 1769 | 0.040 |
Why?
|
| Universities | 1 | 2023 | 956 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2023 | 4445 | 0.040 |
Why?
|
| Comorbidity | 2 | 2023 | 10388 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2023 | 77449 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2022 | 689 | 0.040 |
Why?
|
| Heart Failure | 1 | 2020 | 10900 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2023 | 40561 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2021 | 862 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 3749 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2023 | 63114 | 0.030 |
Why?
|
| Risk Factors | 4 | 2023 | 72290 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2022 | 3913 | 0.030 |
Why?
|
| Fever | 1 | 2022 | 1616 | 0.030 |
Why?
|
| Warfarin | 1 | 2022 | 1496 | 0.030 |
Why?
|
| Axons | 1 | 2022 | 1684 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2023 | 1859 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3508 | 0.030 |
Why?
|
| Young Adult | 3 | 2023 | 56430 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1797 | 0.020 |
Why?
|
| Aortic Valve | 1 | 2020 | 1922 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2022 | 3461 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 2647 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3597 | 0.020 |
Why?
|
| Aged | 4 | 2023 | 163280 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 2104 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 8340 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 20129 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 3158 | 0.020 |
Why?
|
| Software | 1 | 2022 | 4443 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2022 | 53288 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5317 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 4251 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12788 | 0.020 |
Why?
|
| Adolescent | 2 | 2022 | 85781 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8388 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40075 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15295 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 168757 | 0.000 |
Why?
|